300347 Hangzhou Tigermed Consulting
- 54.91
- -0.20-0.36%
Hangzhou Tigermed Consulting News
Tiger Pharmaceuticals (03347) spent 10.157 million yuan to buy back 184,600 A-shares on May 23
According to Zhitong Finance App, Tiger Pharmaceuticals (03347) issued an announcement. On May 23, 2024, for the first time, the company repurchased 184,600 shares of the company's shares through a special stock repurchase securities account through centralized bidding transactions, accounting for 0.0213% of the company's current total share capital and 0.0249% of the company's current total A-share capital. The highest transaction price was RMB 55.15 per share, the lowest transaction price was RMB 54.89 per share, and the total transaction amount was RMB 10.157 million (excluding transaction fees). This repurchase complies with the requirements of the company's share repurchase plan and related laws and regulations.
Changes in Hong Kong stocks | CRO concept stocks declined in the afternoon, minutes of the Federal Reserve meeting, Phased adjustment of Eagle Pharmaceutical Investment and financing
The decline in CRO concept stocks widened in the afternoon. As of press release, Kanglong Chemical (03759) fell 3.99% to $10.58; Tiger Pharmaceuticals (03347) fell 3.93% to HK$34.25; and Kingsley Biotech (01548) fell 3.86% to $10.96.
Pacific Securities: The pharmaceutical industry is under short-term pressure, and future policies will be frequent or enhance the certainty of clinical CRO benefits
With the end of the Fed's interest rate hike cycle, gradual easing of liquidity is expected to bring about a recovery in investment and financing, and overseas demand will improve ahead of local demand; future innovative drug support policies may be introduced intensively, and clinical CRO benefits are highly certain.
Is There An Opportunity With Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) 34% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hangzhou Tigermed Consulting fair value estimate is CN¥88.28 Hangzhou Tigermed Consulting is estimated to be 34% undervalued based on current
Trending Industry Today: GENSCRIPT BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 21st - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending lower today with 9 constituents down and GENSCRIPT BIO leading Losses.$GENS
Changes in Hong Kong stocks | CRO concept stocks collectively declined, and many Federal Reserve officials Fangying Pharmaceutical Outsourcing began to adjust business in the US
The Zhitong Finance App learned that CRO concept stocks were collectively lower. As of press release, Kingsley Biotech (01548) fell 4.77% to 11.58 yuan; Gloria Ying (06821) fell 4.27% to 61.65 yuan; Kanglong Chemical (03759) fell 3.65% to 11.08 yuan; Pharmaceuticals (02359) fell 3.46% to HK$39.1; Tiger Pharmaceuticals (03347) fell 3.35% to HK$34.6. According to the news, a number of Federal Reserve officials said in their Monday speech that more progress is needed on the inflation issue before interest rate cuts can be obtained
Changes in Hong Kong stocks | CRO concept stocks are generally weakening, and many companies have responded once again by overwhelmingly passing the new US Biosafety Act
The Zhitong Finance App learned that CRO concept stocks have generally weakened. As of press release, Tiger Pharmaceuticals (03347) fell 3.3% to HK$35.15; Kingsley Biotech (01548) fell 1.44% to $12.28; Pharmaceutical Kangde (02359) fell 1.21% to $40.7; and Gloria Ying (06821) fell 0.94% to $63.55. According to the news, on the morning of May 15, local time, the US House of Representatives passed the new “Biosafety Act” with a 40-1 vote in a subordinate committee hearing. The new version of the Act requires the companies involved to have existing contracts/products
Interpretation of ESG Annual Report|Tiger Pharmaceuticals (03347) Releases 2023 ESG Report to Deepen Science and Innovation Development Capabilities and Promote the Sustainable Development of Healthcare
Recently, Tiger Pharmaceuticals (03347) released the “2023 Sustainability and Environmental, Social and Governance Report”. This report is the sixth sustainability report issued by Tiger Pharmaceuticals, which discloses the company's actions and progress in the fields of corporate governance, environment and society to key stakeholders.
Tiger Pharmaceuticals (03347) received additional pledges from shareholder Cao Xiaochun and partial share repurchases and cancellation of pledges
Tiger Pharmaceuticals (03347) issued an announcement. The company recently received a notice from Ms. Cao Xiaochun, a shareholder holding more than 5% of the company's shares,...
Trending Industry Today: WUXI APPTEC Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 14th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 9 constituents up and WUXI APPTEC leading Gains.$WUXI APPTE
Tiger Pharmaceuticals (03347.HK) plans to participate in the 2024 Online Investor Group Reception Day for Listed Companies in Zhejiang
Gelonghui, May 9, 丨 Tiger Pharmaceuticals (03347.HK) announced that in order to further enhance interaction with investors, Hangzhou Tiger Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the “Company”) will participate in the “2024 Zhejiang Listed Companies Investor Group Reception Day” jointly organized by the Zhejiang Securities Regulatory Bureau, Zhejiang Listed Companies Association and Shenzhen Panorama Network Co., Ltd. The relevant matters are now announced as follows: The event will be held remotely via the Internet. Investors can log on to the “Panorama Roadshow” website (or follow the WeChat account: Panorama Finance, or download Panorama) Roadshow app, participate in this event
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Zhitong Hong Kong Stock Exchange Unravels | A-shares make up gains and continues to boost Hong Kong stocks need to be wary of attacking Rafah
The current problem with Hong Kong stocks is nothing more than a matter of profit digestion, but under the stimulus of the money-making effect, the entry of incremental capital is expected to form a hedge
Hong Kong stocks closed (05.06) | The Hang Seng Index closed up 0.55% to reap the Shilianyang CRO concept, strong high-speed rail infrastructure stocks, and domestic housing stocks fell across the board
The US non-farm payrolls data for April fell short of expectations, and expectations of market interest rate cuts rebounded somewhat. Hong Kong stocks bottomed out and rebounded today. The three major indices all turned red. The Hang Seng Index successfully reaped 10 consecutive days, and the Hengke Index also reached the 4,000 point mark.
Trending Industry Today: WUXI BIO Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 6th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up, 1 constituents down and WUXI BIO leading
Direct impact of changes | Yao Ming Biotech rose more than 7% to lead CRO concept stocks. The Federal Reserve may still cut interest rates during the year, and overseas demand is expected to resume
On May 6, CRO concept stocks had the highest gains in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 6.82% to HK$36.8; Pharmaceutical Biotech (02269) rose 5.87% to HK$36.45; Kanglong Chemical (03759) rose 4.92% to HK$10.44; and Pharmaceuticals Kangde (02359) rose 3.14% to HK$37.75.
Changes in Hong Kong stocks | CRO concept stocks fell across the board, Yakming Kangde (02359) fell more than 7%, leading the decline, and the company's profit margin for the first quarter fell short of expectations
CRO concept stocks fell across the board. As of press release, Yao Ming Kangde (02359) fell 6.47% to 36.15 yuan; Gloria Ying (06821) fell 5.33% to 63.05 yuan; Kanglong Chemical (03759) fell 4.96% to HK$9.96.
Tiger Pharmaceuticals (03347) plans to spend 500 million to 1 billion yuan to buy back no less than 13.8889 million shares
Tiger Pharmaceuticals (03347) issued an announcement. The company announced on February 6, 2024 and April 12, 2024, respectively...
Tiger Pharmaceuticals (03347) will pay a final dividend of 5.68 yuan for 10 shares on July 31
According to Zhitong Finance App, Tiger Pharmaceuticals (03347) announced that the company will pay a final dividend of 5.68 yuan for 10 shares on July 31, 2024.
泰格醫藥：2023年股東週年大會通告
Analysis
Price Target
No Data
